Monica M Mita

Summary

Affiliation: Cancer Therapy and Research Center
Country: USA

Publications

  1. ncbi Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 4th Floor Zeller Building, 7979 Wurzbach Road, San Antonio, TX 78229, USA
    Clin Colorectal Cancer 4:107-23. 2004
  2. ncbi Mammalian target of rapamycin: a new molecular target for breast cancer
    Monica M Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Clin Breast Cancer 4:126-37. 2003
  3. ncbi The role of mTOR inhibitors for treatment of sarcomas
    Monica M Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78230, USA
    Curr Oncol Rep 9:316-22. 2007
  4. ncbi Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation
    Jennifer S Carew
    Institute for Drug Development, University of Texas Health Science Center, San Antonio, TX 78245, USA
    J Cell Mol Med 14:2448-59. 2010
  5. ncbi Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Chia Chi Lin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 63:1065-71. 2009
  6. ncbi Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
    Monica M Mita
    Cancer Therapy and Research Center, Institute for Drug Development, The University of Texas Health Science Center, San Antonio, TX, USA
    J Clin Oncol 26:361-7. 2008
  7. ncbi Targeting sarcomas: novel biological agents and future perspectives
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center, 7979 Wurzbach Road, San Antonio, Texas 78229, USA
    Curr Drug Targets 10:937-49. 2009
  8. ncbi Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, Texas 78245, USA
    Clin Cancer Res 16:141-53. 2010
  9. ncbi Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas
    Monica M Mita
    Institute for Drug Development, San Antonio, Texas, USA
    Clin Cancer Res 16:5892-9. 2010
  10. ncbi Targeting the mTOR pathway using deforolimus in cancer therapy
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Research and Therapy Center, University of Texas Health Science Centre San Antonio, TX, USA
    Future Oncol 5:291-303. 2009

Detail Information

Publications18

  1. ncbi Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 4th Floor Zeller Building, 7979 Wurzbach Road, San Antonio, TX 78229, USA
    Clin Colorectal Cancer 4:107-23. 2004
    ..It will also emphasize the complexity of these systems and the need to incorporate novel clinical development paradigms based on a thorough scientific understanding of these targets...
  2. ncbi Mammalian target of rapamycin: a new molecular target for breast cancer
    Monica M Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Clin Breast Cancer 4:126-37. 2003
    ..The preliminary results of early clinical evaluations with rapamycin analogues and the unique developmental challenges that lie ahead will also be discussed...
  3. ncbi The role of mTOR inhibitors for treatment of sarcomas
    Monica M Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78230, USA
    Curr Oncol Rep 9:316-22. 2007
    ..This article discusses preliminary results from clinical trials in patients with advanced or metastatic sarcoma as well as future perspectives...
  4. ncbi Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation
    Jennifer S Carew
    Institute for Drug Development, University of Texas Health Science Center, San Antonio, TX 78245, USA
    J Cell Mol Med 14:2448-59. 2010
    ..Collectively, our results establish that inhibition of autophagy with CQ induces ubiquitinated protein accumulation and VOR potentiates CQ-mediated aggregate formation, superoxide generation and apoptosis...
  5. ncbi Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Chia Chi Lin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 63:1065-71. 2009
    ....
  6. ncbi Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
    Monica M Mita
    Cancer Therapy and Research Center, Institute for Drug Development, The University of Texas Health Science Center, San Antonio, TX, USA
    J Clin Oncol 26:361-7. 2008
    ....
  7. ncbi Targeting sarcomas: novel biological agents and future perspectives
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Therapy and Research Center at University of Texas Health Science Center, 7979 Wurzbach Road, San Antonio, Texas 78229, USA
    Curr Drug Targets 10:937-49. 2009
    ....
  8. ncbi Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, Texas 78245, USA
    Clin Cancer Res 16:141-53. 2010
    ..Survivin expression has been implicated in drug resistance and reducing its levels with the histone deacetylase (HDAC) inhibitor vorinostat may enhance the anticancer activity of temsirolimus...
  9. ncbi Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas
    Monica M Mita
    Institute for Drug Development, San Antonio, Texas, USA
    Clin Cancer Res 16:5892-9. 2010
    ....
  10. ncbi Targeting the mTOR pathway using deforolimus in cancer therapy
    Devalingam Mahalingam
    Institute for Drug Development, Cancer Research and Therapy Center, University of Texas Health Science Centre San Antonio, TX, USA
    Future Oncol 5:291-303. 2009
    ....
  11. ncbi Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
    Yesid Alvarado
    Department of Hematology Oncology, Institute for Drug Development, The University of Texas Health Science Center San Antonio, TX 78229, USA
    Target Oncol 6:69-94. 2011
    ..This review focuses on a discussion of the pathway, its implications in cancer biology and results of clinical trials of rapalogs alone or in combination, organizing them by common malignancy type...
  12. ncbi Heat shock proteins: a potential anticancer target
    Kamalesh K Sankhala
    Institute for Drug Development at CTRC, The University of Texas Health Science Center, San Antonio, TX, USA
    Curr Drug Targets 12:2001-8. 2011
    ..The universal involvement of Hsp90 in multiple oncogenic processes makes Hsp90 inhibitors ideal compounds to be explored as a single agent or in combination with other anticancer therapies...
  13. ncbi A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma
    Monica M Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 59:165-74. 2007
    ....
  14. ncbi Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas, USA
    Clin Cancer Res 13:3293-301. 2007
    ..v. infusion without premedication every 3 weeks, determine the maximum tolerated dose and the phase II recommended dose of AI-850, study the pharmacokinetics of paclitaxel in this new formulation, and seek evidence of anticancer activity...
  15. ncbi Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 12:7406-13. 2006
    ....
  16. ncbi Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, 7979 Wurzbach Road, San Antonio, TX 78229, USA
    Clin Cancer Res 14:5000-5. 2008
    ..This article reviews the multiple functions of survivin in the regulation of apoptosis, the promotion of tumorigenesis, and the development of survivin inhibitors as a novel anticancer therapeutic strategy...
  17. ncbi Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
    John Nemunaitis
    Mary Crowley Cancer Research Centers, Dallas, TX 75201, USA
    Cancer Chemother Pharmacol 71:35-41. 2013
    ..This study assessed pharmacokinetics and safety of SC omacetaxine in patients with advanced cancers...
  18. ncbi The molecular target of rapamycin (mTOR) as a therapeutic target against cancer
    Monica M Mita
    Institute for Drug Development Cancer Therapy and Research Center San Antonio, Texas 78229, USA
    Cancer Biol Ther 2:S169-77. 2003
    ..The preliminary results of early clinical evaluations with RAP analogs and the unique developmental challenges that lie ahead will also be discussed...